Pyr-Ala | 2392-63-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Pyr-Ala
• 英文别名: N-Pyruvyl-L-alanin；N-(2-Oxopropanoyl)-L-alanine；(2S)-2-(2-oxopropanoylamino)propanoic acid
• CAS: 2392-63-4
• 化学式: C₆H₉NO₄
• 分子量: 159.142
• InChiKey: LRBARJMHQPHPQP-VKHMYHEASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  Pyr-Ala 在 氯乙酰氯 作用下， 以 氯仿 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  一种恩利卡生的合成方法

  摘要：

  一种恩利卡生的合成方法，属于药物化学合成技术领域。步骤：先由丙酮酸与酰氯化试剂进行酰氯化反应，得到丙酮酰氯，再将丙酮酰氯和L‑丙氨酸甲酯进行缩合反应，得到中间体（I）；将中间体（I）进行水解反应，得到羧酸衍生物，将羧酸衍生物与酰氯化试剂进行酰氯化反应，得到酰氯衍生物，再将该酰氯衍生物进行缩合反应，得到中间体（II）；将中间体（II）进行氧化反应，得到羧酸衍生物，将该羧酸衍生物与酰氯化试剂进行酰氯化反应，得到酰氯衍生物，再将酰氯衍生物进行缩合反应，得到叔丁酯衍生物，再将该叔丁酯衍生物用三氟乙酸处理，进行水解反应，得到成品恩利卡生。简化操作，每一步都能获得较高的收率；满足工业化放大生产要求。

  公开号：

  CN105017061B
• 作为产物：
  描述：

  N-Pyruvoyl-L-alanin-methylester 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 Pyr-Ala
  参考文献：
  名称：

  一种恩利卡生的合成方法

  摘要：

  一种恩利卡生的合成方法，属于药物化学合成技术领域。步骤：先由丙酮酸与酰氯化试剂进行酰氯化反应，得到丙酮酰氯，再将丙酮酰氯和L‑丙氨酸甲酯进行缩合反应，得到中间体（I）；将中间体（I）进行水解反应，得到羧酸衍生物，将羧酸衍生物与酰氯化试剂进行酰氯化反应，得到酰氯衍生物，再将该酰氯衍生物进行缩合反应，得到中间体（II）；将中间体（II）进行氧化反应，得到羧酸衍生物，将该羧酸衍生物与酰氯化试剂进行酰氯化反应，得到酰氯衍生物，再将酰氯衍生物进行缩合反应，得到叔丁酯衍生物，再将该叔丁酯衍生物用三氟乙酸处理，进行水解反应，得到成品恩利卡生。简化操作，每一步都能获得较高的收率；满足工业化放大生产要求。

  公开号：

  CN105017061B

文献信息

• Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
  申请人：Garvey David S.

  公开号：US20080287407A1

  公开（公告）日：2008-11-20

  The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

  该发明描述了新颖的硝化和/或亚硝化丙酮酸盐及其药用可接受盐，以及包含至少一种硝化和/或亚硝化丙酮酸化合物的新型组合物，以及可选地，至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或至少一种治疗剂。该发明还提供了包含至少一种丙酮酸化合物和至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种丙酮酸化合物的新型试剂盒，该丙酮酸化合物可选地硝化和/或亚硝化，以及可选地至少一种一氧化氮供体和/或至少一种治疗剂。该发明还提供了治疗由氧化应激、糖尿病、缺血后再灌注损伤、组织、器官、器官部分和/或肢体保护引起的疾病的方法。
• Intracellular Oxidation of Dipeptides. Base-Promoted Elimination from <i>N</i>-Halodipeptides to 2-[<i>N</i>-Alkyl-<i>N</i>-(2-<i>N</i>-alkylimino-2-alkylethanoyl)amino]-2,2-dialkylethanoic Acids
  作者：X. L. Armesto、M. Canle L.、M. I. Fernández、M. V. García、S. Rodríguez、J. A. Santaballa

  DOI：10.1021/jo001336u

  日期：2001.8.1

  via the formation of the corresponding (N-X)-dipeptides, that then undergo base-promoted elimination to yield intermediate 2-[N-alkyl-N-(2-N-alkylimino-2-alkylethanoyl)amino]-2,2-dialkylethanoic acids, which subsequently hydrolyze. Such an elimination process is general-base catalyzed, with Brønsted beta values ranging from 0.26 to 0.31, which suggests an essentially constant degree of proton transfer

  肽的细胞内氧化的可能方式之一是通过形成相应的（NX）-二肽，然后对其进行碱促进的消除，以生成中间体2- [N-烷基-N-（2-N-烷基亚氨基-2） -烷基乙酰基）氨基] -2，2-二烷基乙酸，其随后水解。这种消除过程是通用碱催化的，布朗斯台德β值在0.26到0.31之间，这表明质子在TS处的转移程度基本恒定。对于（NX）-二肽，比率k（N-Br）/ k（N-Cl）为2.5至15，表明在TS处NX键断裂程度的结构依赖性。β和k（N-Br）/ k（N-Cl）的值支持协调一致的异步A（xh）D（H）D（N）机制，其TS取决于反应物从类反应物变为类to起始二肽的结构。由于该反应需要抗平面性，因此离去基团与带有要被除去的H的C上的取代基之间的空间相互作用控制了反应速率。如空间交叉相互作用系数（p（ssy′）＝ 0.33）所示，这种空间相互作用是相当重要的。半经验计算表明，反应中心附近的大取代基意味着
• Assays, methods and means
  申请人：Maxwell Patrick Henry

  公开号：US20100272726A1

  公开（公告）日：2010-10-28

  A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity.

  本文描述了一种新型的羟化酶，其氨基酸序列为SEQ ID NO：2、4、6和8，以及具有HIF羟化活性的变体和片段。本发明的多肽特别具有脯氨酸羟化酶活性。一种测定方法监测HIF羟化酶与底物的相互作用。提供了HIF羟化酶的调节剂，用于治疗与HIF水平或活性增加或减少相关的疾病，或用于治疗需要调节HIF水平或活性的疾病。
• Sustained release dosage form having latex coating and method of making the same
  申请人：ABBOTT LABORATORIES

  公开号：EP1579853A2

  公开（公告）日：2005-09-28

  Dosage form unit is provided to deliver one or more beneficial agents into a fluid, such as liquid enteral nutritional product. The dosage form unit includes a core containing at least one beneficial agent, preferably a marker dye, which is dispersible in the fluid. The core also contains a compatible binding agent to bind the beneficial agent together. Additional components of the core may include a plasticizer, a standard flow agent, a lubricant, additional tableting aids and at least one hydrophilic agent. A latex coating encases the core. The latex coating includes a mixture containing a substantially hydrophobic base material, preferably formed from an emulsion of cellulose acetate microspheres, which is capable of defining a matrix-type membrane, and at least one hydrophilic component being dispersible in the fluid. A dispersible beneficial agent is preferred as one of the hydrophilic components of the latex coating to allow immediate release of the beneficial agent therefrom. A method of making the dosage form unit also is provided.

  所提供的剂型单元可将一种或多种有益制剂输送到液体中，如液体肠内营养产品。该剂型装置包括一个内核，内核含有至少一种可分散在液体中的有益制剂，最好是标记染料。核心还含有一种兼容的结合剂，可将有益制剂结合在一起。核心的其他成分可包括增塑剂、标准流动剂、润滑剂、其他制片助剂和至少一种亲水剂。乳胶涂层包裹芯材。乳胶涂层包括一种混合物，其中包含一种基本疏水的基质材料，最好是由醋酸纤维素微球乳液形成，它能够形成基质型膜，以及至少一种可在流体中分散的亲水成分。乳胶涂层的亲水成分之一最好是可分散的有益剂，以便有益剂能立即从涂层中释放出来。此外，还提供了一种制造剂型单元的方法。
• Compositions and methods for the treatment and prevention of chronic hypoxemia and dyspnea
  申请人：Martin Alain

  公开号：US10813893B2

  公开（公告）日：2020-10-27

  The present invention has shown that not all salts of pyruvic acid enhance lung functions or enhance the synthesis of lung surfactants and that certain salts of pyruvic acid with the correct concentrations of calcium, phosphate and magnesium, are synergistic in their ability to enhance the synthesis of lung surfactants that will enhance lung alveoli functions, while decreasing coughing and lung tightness, and increasing oxygen saturation values to prevent hypoxemia. This patent demonstrates that the sodium pyruvate formula with calcium, phosphate and magnesium was superior over standard sodium pyruvate formula in saline alone in the removal of mucus, reduction of lung or sinus infections, and in reducing drug side effects and congestion. The use of this formula clearly demonstrated that it can be used to produce better efficacy in patients with hypoxemia, with lung and sinus diseases including, asthma, COPD, cystic fibrosis, interstitial lung disease, allergic rhinitis, sinusitis, Alzheimer's, disease, Parkinson's disease, brain trauma, nicotine addiction, sleep apnea, autism, migraine headaches, sleep disorders, lung and sinus infections, cancer therapy with cancer drugs, nicotine addiction, and medications that cause a decrease in lung surfactants.

  本发明表明，并非所有丙酮酸盐都能增强肺功能或促进肺表面活性物质的合成，某些丙酮酸盐与正确浓度的钙、磷酸盐和镁协同作用，能够促进肺表面活性物质的合成，从而增强肺泡功能，同时减少咳嗽和肺部紧绷感，提高血氧饱和度值，防止低氧血症。本专利证明，在清除粘液、减少肺部或鼻窦感染、减轻药物副作用和充血方面，含钙、磷酸盐和镁的丙酮酸钠配方优于仅在生理盐水中添加的标准丙酮酸钠配方。病、帕金森病、脑外伤、尼古丁上瘾、睡眠呼吸暂停、自闭症、偏头痛、睡眠障碍、肺部和鼻窦感染、使用抗癌药物进行癌症治疗、尼古丁上瘾以及导致肺表面活性物质减少的药物。